Coherus Oncology (CHRS) FCF Margin Growth (5y) (2019 - 2026)

Coherus Oncology (CHRS) FCF Margin Growth (5y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -47,171.00
Dec 31, 2025 -24,950.00
Sep 30, 2025 -44,032.00
Jun 30, 2025 421,688.00
Mar 31, 2025 -41,203.00
Dec 31, 2024 35,672.00
Sep 30, 2024 -107,394.00
Jun 30, 2024 95,369.00
Mar 31, 2024 626,616.00
Jun 30, 2022 395,357.00
Mar 31, 2022 4.65 Mn
Dec 31, 2021 1.10 Mn
Sep 30, 2021 5,435.00
Jun 30, 2021 17,811.00
Mar 31, 2021 63,635.00
Dec 31, 2020 -2,545.00
Sep 30, 2020 87,164.00
Jun 30, 2020 32,698.00
Mar 31, 2020 60,172.00
Dec 31, 2019 48,990.00